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Abstract
Background: Smoking tobacco is a leading cause of chronic obstructive pulmonary disease (COPD), but although
the majority of COPD cases can be directly related to smoking, only a quarter of smokers actually develop the
disease. A potential reason for the disparity between smoking and COPD may involve an individual’s ability to
mount a protective adaptive response to cigarette smoke (CS). Glutathione (GSH) is highly concentrated in the
lung epithelial lining fluid (ELF) and protects against many inhaled oxidants. The changes in GSH that occur with
CS are not well investigated; therefore the GSH adaptive response that occurs with a commonly utilized CS
exposure was examined in mice.
Methods: Mice were exposed to CS for 5 h after which they were rested in filtered air for up to 16 h. GSH levels
were measured in the ELF, bronchoalveolar lavage cells, plasma, and tissues. GSH synthesis was assessed by
measuring g-glutamylcysteine ligase (GCL) activity in lung and liver tissue.
Results: GSH levels in the ELF, plasma, and liver were decreased by as much as 50% during the 5 h CS exposure
period whereas the lung GSH levels were unchanged. Next, the time course of rebound in GSH levels after the CS
exposure was examined. CS exposure initially decreased ELF GSH levels by 50% but within 2 h GSH levels rebound
to about 3 times basal levels and peaked at 16 h with a 6-fold increase and over repeat exposures were
maintained at a 3-fold elevation for up to 2 months. Similar changes were observed in tissue GCL activity which is
the rate limiting step in GSH synthesis. Furthermore, elevation in ELF GSH levels was not arbitrary since the CS
induced GSH adaptive response after a 3d exposure period prevented GSH levels from dropping below basal
levels.
Conclusions: CS exposures evoke a powerful GSH adaptive response in the lung and systemically. These data
suggests there may be a sensor that sets the ELF GSH adaptive response to prevent GSH levels from dipping
below basal levels. Factors that disrupt GSH adaptive responses may contribute to the pathophysiology of COPD.
Introduction
The lung is unique since it is exposed to high ambient
oxygen levels and a constantly changing atmospheric
environment. The lung is exposed on a daily basis to a
wide range of oxidants ranging from ozone, smog, diesel
exhaust, dust particles and cigarette smoke (CS). In
comparison to all other forms of inhaled oxidants, CS
m a yb eo n eo ft h em o s tp r e v a l e n ta n dp r e v e n t a b l eo x i -
dant exposures, with nearly 1 billion smokers worldwide.
CS contains at least 4,800 different chemicals with over
10
14 radicals per puff that can cause DNA, protein, and
lipid oxidation among many other effects [1-3].
Fortunately, the lung has developed adaptive mechan-
isms to defend itself against inhaled oxidants [4].
CS is the primary cause of chronic obstructive pul-
monary disease (COPD), with as much as 90% of
COPD patients having been smokers at one point in
their lifetime [5,6]. However, a conundrum exists in
that not all smokers go on to develop COPD. It has
been estimated that only about 25% of smokers develop
COPD, typically later in life [7]. The fact that 75% of
smokers do not develop COPD points to strong defense
mechanisms to handle the increased oxidant burden
that smoking puts on the lung. Furthermore, the effects
of CS are not limited only to the lung. CS has been
implicated in several cardiovascular diseases, liver dis-
eases as well cancer [8,9].
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epithelial lining fluid (ELF) [4]. The ELF is a thin contin-
uous fluid that hydrates the epithelial cells throughout
the airways. The ELF is comprised of a heterogeneous
mixture of mucus, cells, proteins, and low molecular
weight antioxidants [4]. At its most basic, the ELF pro-
vides a physical barrier against many inhaled oxidants
and an important component of host defense against
pathogens. In addition to being able to act as a physical
barrier, there are high concentrations of antioxidants
within the ELF that act to detoxify exogenous or endo-
genous oxidants [4,10,11]. One of these antioxidants is
glutathione (GSH) which is concentrated in the ELF 10-
100 times more than in the plasma [12]. GSH is a tripep-
tide comprised of glutamate, cysteine, and glycine and is
synthesized and utilized in every organ throughout the
body. g-Glutamylcysteine ligase (GCL) is the rate limiting
enzyme involved in GSH synthesis and its expression has
been shown to be induced in response to CS [13]. GSH
can react with a wide range of molecules, making it an
effective antioxidant at detoxifying many of the diverse
reactive electrophilic components of CS.
CS has been shown to induce a number of different
antioxidant defenses including the expression of enzymes
and transcription factors that lead to increased synthesis
of GSH [14]. This increase GSH response to CS is
referred to as the GSH adaptive response. Despite being
a potentially critical antioxidant, not much is known
about the acute effects of CS on the GSH adaptive
response and how GSH levels can fluctuate both during
and between CS exposures especially in the lung ELF.
Therefore the present study sought to characterize the
changes in GSH with exposure to CS in various compart-
ments with an emphasis on the changes that occur in the
ELF both during and between acute CS exposures in vivo.
Methods
Cigarette smoke extract (CSE) preparation
The smoke of one 3R4F Kentucky reference cigarette
was bubbled through 7 mL of room temperature PBS.
The extract was measured spectrophotometrically at a
wavelength of 210 nm, an absorbance of 1.3-2.0 was
considered acceptable. The resulting extract was deemed
100% CSE and was diluted in normal cell media.
In vitro CSE exposure
Human bronchial epithelial cell line (16HBE, ATCC)
was grown in DMEM supplemented with glutamine,
10% FBS and antibiotics. Cells were grown to roughly
85% confluence and CSE was diluted in the media to a
final concentration of 20%. The cells were exposed for
various times, after which the media was removed and
the cells were washed with warm PBS and lysed by brief
sonication in fresh PBS. Media and lysate was stored at
-20°C until analysis. Cytotoxicity was assessed by mea-
suring lactate dehydrogenase release as previously
described [15] and CSE treated cells under conditions
tested did not have changes in cell viability that were
statistically significantly different from controls and was
greater than 85%.
In vivo cigarette smoke (CS) exposure
Male C57B/6 two month old mice were obtained from
Jackson’s laboratory (Bar Harbor, ME). The mice were
exposed to CS from Kentucky reference cigarette 3R4F
(University of Kentucky) for 5 h/day. The average parti-
culate matter was 100 mg/m
3 and carbon monoxide
levels were less than 350 ppm. Unless explicitly stated
the mice were sacrificed 16 h after the CS exposure via
cardiac exanguastion and bronchoalveolar lavage (BAL)
was performed using two 750 μL rinses of cold isotonic
potassium phosphate solution. The dilution of the ELF
was calculated by measuring urea in both the BAL fluid
(BALF) and plasma as previously reported [16]. All ani-
mal procedures followed the Public Health Service Pol-
icy on Humane Care and Use of Laboratory Animals
and received prior approval by the National Jewish
Health IACUC committee.
Tissue collection
Both BALF and whole blood were kept on ice and then
centrifuged to separate the BAL cells and plasma,
respectively. The lungs and liver were perfused using
PBS and snap frozen in liquid nitrogen. Tissues were
stored at -80°C until analysis. For tissue analysis, roughly
25 mg tissue was homogenized in 0.5 mL potassium
phosphate buffer. The resulting solution was clarified of
cell debris by centrifugation and analyzed for GSH levels
or GCL activity.
Measurement of glutathione
Total glutathione (GSH) was measured spectrophotome-
trically in the BALF, plasma, and tissues as previously
described [17]. GSH was measured by adding the stan-
dard or sample to 100 μLo fa1 : 1m i x t u r eo f3u n i t s /
mL glutathione reductase with 0.67 mg/mL 5,5’-Dithio-
bis(2-nitrobenzoic acid) (DTNB). The reaction was
initiated by the addition of 20 μLo f0 . 6 7m g / m L
NADPH and the increase in absorbance at 412 nm was
monitored. Values measured in BALF were normalized
to urea, values in tissues were normalized to protein
content. For in vitro samples both the media and lysate
were normalized to the lysate protein. The limit of
detection for GSH was 0.2 μM.
Measurement of g-glutamylcysteine ligase (GCL) activity
GCL activity was measured in lung and liver homoge-
nates as previously described [18]. Samples were split
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standard was added to GCL reaction buffer (400 mM
Tris, 40 mM ATP, 20 mM L-glutamic acid, 2.0 mM
EDTA, 20 mM sodium borate, 2 mM serine, and 40
mM MgCl2). The reaction was initiated using 2 mM
cysteine added to the GCL activity samples and allowed
to incubate for 30 min. The reaction was halted by the
addition of sulfosalicylic acid and protein precipitate was
removed by centrifugation. Standard or sample was
transferred in triplicate to a 96-well plate and GSH was
then derivitized by the addition of 10 mM 2,3-naphtha-
lenedicarboxyaldehyde and the fluorescence at Ex/Em
wavelength of 472/528 nm was quantified using a fluor-
escent plate reader (Synergy 2, BioTek). GCL activity
was calculated as the difference in GSH concentration
between the reaction and baseline samples per minute
normalized to the protein content in the sample.
Statistics
Data represented as mean ± standard error with an n =
5 for each group. One way analysis of variance with
Newman-Keuls post test for multiple comparisons was
run using Prism 5 software (Graphpad). Different letters
above each group denotes a significant difference (p <
0.05) between groups.
Results
Airway epithelial cells export GSH in response to CSE
over time
Bronchial epithelial cells were exposed to CSE for 12,
24, and 48 hours to determine whether cells retain or
export GSH in response to the CSE exposure. No
change in extracellular GSH levels were observed after
12 hours of CSE exposure, but by 24 and 48 hours there
was significantly more extracellular GSH with CSE
exposure versus the control (Figure 1A). There was no
change in viability between the control and CSE exposed
cells at any timepoint (data not shown), which supports
cells actively exporting GSH rather than it being
released due to cell lysis. Additionally, the intracellular
GSH was not changed at 12 hours between control and
CSE but by 24 and 48 hours there was significantly
increased intracellular GSH in the CSE exposed cells
(Figure 1B).
Lung ELF GSH is maintained over repeated CS exposures
Mice were exposed to CS for 5 h/d for various times to
determine when the ELF GSH adaptive response was
maximal (Figure 2). The GSH adaptive response in the
ELF peaked after one day of CS exposure, with nearly
600 μM GSH in the ELF. By day 3, the ELF GSH was
actually less than the first day at only 250 μM. The
same GSH levels after 3 days was maintained in the ELF
over extended exposures up to 120 days. Due to the
Figure 1 Airway cells export GSH in response to CSE over time.
The extracellular (A) and intracellular (B) GSH levels after the
exposure of 16HBE cells to 20% CSE at 12, 24, and 48 hours. Data
represented as mean ± SEM, with different letters representing
statistically significant differences between groups, p < 0.05.
Figure 2 Epithelial lining fluid (ELF) GSH levels with repeated
CS exposures. Mice were exposed to CS for 5 days/week between
1 and 120 days. ELF GSH levels are highest after 1 day of CS
compared to repeated exposures. Data represented as mean ± SEM,
with different letters representing statistically significant differences
between groups, p < 0.05.
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sures, it stands to reason that the GSH adaptive
response was established early, within 1 day, and then
maintained for extended periods of time.
CS exposure acutely depletes GSH levels
We sought to determine the effect of CS exposure on
t h eG S Hl e v e l sb e f o r et h ea d a p t i v er e s p o n s eh a db e e n
established since many of the GSH changes are estab-
lished within an acute timeframe. Mice were exposed to
CS for 1, 4, or 5 hours and then sacrificed immediately
following the smoke exposure. CS exposure depleted
ELF GSH levels by 4 hours from 100 μMt o2 5μM,
which was roughly the level where it remained until the
end of the CS exposure (Figure 3A). Furthermore, in
both the plasma (Figure 3C) and liver (Figure 3D) there
was a 50% decrease in GSH levels following all of the
CS exposure times. Interestingly, the lung GSH (Figure
3B) was maintained at the same level throughout the CS
exposure.
GSH levels rebound between CS exposures
Lung ELF GSH levels were reduced immediately follow-
ing the CS exposure, yet after the first day of exposure
to CS the GSH levels greatly rebound during the rest
periods. The rest period between CS exposures was typi-
cally overnight, generally about 16 hours. To investigate
this rebound period, mice were exposed to CS for 5
hours and then allowed to rest in a room receiving fil-
t e r e da i rf o r0 ,2 ,4 ,8 ,o r1 6h o u r s .T h eG S Hl e v e l si n
Figure 3 Changes in GSH levels that occur during the CS exposure. Mice were exposed to CS for 1, 4 or 5 hours and sacrificed immediately
following exposure. ELF (A), plasma (C), and liver (D) GSH levels fell during the CS exposure while lung (B) GSH levels were maintained
throughout the exposure. Data represented as mean ± SEM, with different letters representing statistically significant differences between
groups, p < 0.05.
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ure 4D) were slightly reduced immediately following the
CS exposure with no rest period, while the lung (Figure
4B) was not changed. As expected the GSH levels
rebound during the rest period, with the ELF GSH levels
rising to about 250 μM within the first 2 hours. Addi-
tionally, the depleted plasma and liver levels also
rebound back to control levels. Intriguingly the plasma
GSH levels spike to about 13 μMa t4h o u r sw h i l et h e
ELF GSH peaks at nearly 500 μM by 8 hours. These
changes were mirrored by changes in the lung (Figure
5 A )a n dl i v e r( F i g u r e5 B )t i s s u eG C La c t i v i t yw h i c hi sa
good indicator of a tissue’s capacity to maintain GSH
levels. This data shows that while the GSH was initially
depleted by CS, the adaptive response was initiated and
within 2 hours GSH levels return to normal and then
rose above normal levels.
GSH adaptive response prevents CS induced GSH
depletion
There appears to be two distinct phases of the GSH
adaptive response to CS exposures starting with an
initial GSH adaptive response and then a maintained
GSH response in the ELF. The ELF GSH levels that
occur with the initial adaptive response are roughly 500-
600 μM (Figure 1A and 4A) while the GSH levels for
Figure 4 GSH levels rebound during CS exposure recovery period. The normal recovery period between smoke exposures is overnight
which is typically about 16 hours. Mice were exposed to CS for 5 h and allowed to recover between 0 and 16 hours. ELF (A) GSH levels
rebounds within 2 hours after exposure and peaks at 8 hours while plasma (C) GSH levels peak at 4 hours after CS exposure. The liver (D) GSH
levels also rebound back to control levels and the lung (B) GSH levels are unchanged. Data represented as mean ± SEM, with different letters
representing statistically significant differences between groups, p < 0.05.
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exposures are only about 250-300 μM( F i g u r e1 A ) .W e
sought to determine whether the maintained adaptive
level was sufficient to prevent CS induced GSH deple-
tion upon repeated CS exposures. Mice were exposed to
CS for 3 days to achieve an adaptive GSH level of
roughly 250 μM and they were sacrificed immediately
after the third day of CS exposure or after 16 hours of
rest (Figure 6). The ELF GSH levels after the rest period
was the expected 250 μM but when the mice were sacri-
ficed immediately followingt h et h i r dd a yo fC Se x p o -
sure the ELF GSH levels were no different than control
levels unlike the naïve mice which CS exposure depleted
the ELF GSH levels by 50% (Figure 4A). This data sug-
gests that the ELF GSH level of the maintained adaptive
response is calibrated to prevent the CS-induced deple-
tion of GSH levels below basal levels.
Discussion
COPD is a disease that takes decades to develop. Not all
smokers develop COPD, but of those that do, the vast
majority are over 60 years old [19]. Both COPD and
lung cancer show a separation in the time between the
exposure and actual disease symptoms, which for COPD
can be 30 years or more. This is one of the largest chal-
lenges to understanding the effects of CS and how it
leads to COPD. Among researchers studying CS-
induced lung damage the most common animal model
of chronic exposure uses a smoking regime of 5 hours
per day, 5 days per week. This regimen has been shown
to be effective at causing airway enlargement in rodents
after at least 6 full months of CS exposure [20,21]. How-
ever, little is known about the early changes that allow
t h el u n gt ob ea b l et ow i t h s t a n dt h eo x i d a n ti n s u l to f
CS for such a long time. Many acute studies utilize a
completely different exposure pattern with very high CS
concentrations, which is not necessarily comparable to
the smoking regimen used for chronic studies [22,23].
I nt h ep r e s e n ts t u d yw eh a v ee x a m i n e dG S Hc h a n g e s
using the most common rodent exposure regimen for
chronic CS studies and have shown that there is a GSH
adaptive response to CS that occurs very early on and
can be maintained for periods of up to 4 months.
Figure 5 GSH synthesis increases during the CS exposure
recovery periods in both the lung and liver. g-Glutamylcysteine
ligase (GCL) is the rating limiting step in GSH synthesis and it was
measured in the lung (A) and liver (B) at multiple time points
during the CS exposure and during the recovery period. Data
represented as mean ± SEM, with different letters representing
statistically significant differences between groups, p < 0.05.
Figure 6 The maintained GSH adaptive response in the ELF
prevents CS induced GSH depletion below basal levels. The
maintained GSH adaptive response in the ELF occurs within 3 days.
Mice were exposed to CS for 3 days to induce GSH adaptive
responses and ELF GSH levels were analyzed after either 16 hours of
recovery (closed bar) or immediately following the CS exposure
(crossed bar). Data represented as mean ± SEM, with different
letters representing statistically significant differences between
groups, p < 0.05.
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routinely overlooked. Most of the focus is on the
chronic effects of CS, with the rationale that COPD is a
disease that arises from chronic smoking. It is well
established that humans can smoke for years without
any major health complications, while rodents can be
exposed for months on end without any ill effect. Addi-
tionally, only modest effects on airspace enlargement
occur in mice after 6 months of CS exposure [24].
While it is well known that the lung can tolerate CS for
extended periods of time, very little is known about the
mechanisms the lung uses for adaptation.
GSH is one of the most ubiquitous low molecular
weight antioxidants in the body, it is expressed at high
levels within cells and is found at relatively high levels
in some extracellular fluids such as the lung ELF [4] and
bile [25]. In the present study, two phases of the GSH
adaptive response to CS exposure were observed, an
initial exaggerated adaptive response and a maintained
adaptive response. Similar to the responses that occur
with other exposures, GSH is initially increased to very
high levels in the ELF with CS exposure. This response
may be part of an emergency response with the sudden
onslaught of oxidants from the CS exposure or it may
be the depletion of GSH during the CS exposure com-
bined with the increase in oxidants from CS that acts as
a trigger to initiate this response. Similar responses in
GSH adaptive responses have been observed in the liver
with acetaminophen poisoning [26].
One of the more interesting aspects is that while the
CS exposure depletes the ELF, plasma, and liver GSH
levels, the lung tissue GSH levels remain unchanged.
This may be due to the lung utilizing GSH from the
plasma, in turn causing the liver to export more GSH
into the plasma. The ability of the lung to utilize GSH
from the plasma seems evident based on the fact that
during the rest period the plasma GSH spikes at 4
hours while at the same time point the lung GSH is
slightly higher and the ELF GSH is still rising. The simi-
larity in changes in GCL activity in the liver with the
rebound increase in ELF GSH also point to the liver as
a potential source for this GSH. Potentially the lung
may be utilizing GSH from the plasma through an intact
uptake mechanism shown to occur in the lung [27],
which is then apically transported into the ELF, result-
ing in no net change in lung tissue GSH but a drastic
i n c r e a s ei nE L FG S H .T h e s ed a t as u g g e s t st h a tG S Hi n
the ELF may in fact originate from the plasma and hints
at a strong reliance of the lung on the inter-organ sup-
ply of GSH especially during oxidative stress.
The GSH response with repeated exposures is also
very interesting since the level of GSH in the ELF is
established at a lower, but still protective level within
t h ef i r s t3d a y so fC Se x p o s u r e .M o r ei m p o r t a n t l y ,
comparable levels are maintained for at least 4 months
that suggests these adaptive responses are established
early and can be maintained for extended periods of
time. This may also give insight into why rodents, and
potentially humans, can tolerate CS for long periods of
time. It is conceivable that all or part of the adaptive
response is broken or defective early in the disease pro-
cess or becomes insufficient due to age-related decline
in GSH levels [16].
Another interesting facet of the maintained adaptive
response is that the GSH level of roughly 250-300 μM
may not be arbitrary. It seems as though the amount of
GSH depletion that occurs during the CS exposures
may trigger the amount of GSH that is maintained in
the ELF between exposures. This suggests that there is
some component in the ELF or lung that can act as a
sensor to titrate the increase in GSH levels to prevent
the ELF GSH level from dropping below basal levels.
Some of the possible factors that are abundant in CS
are polyaromatic hydrocarbons (PAHs) that are inducers
of cytochrome P450s and are well known sources of
reactive oxygen species [28]. This source of oxidative
stress could maintain elevated levels of GSH observed
with CS exposures. Another potential regulator of the
chronic GSH adaptive response to CS exposure are the
glutathione-S-transferases (GSTs) that conjugate GSH to
xenobiotics for transport that could stimulate an
increase in GSH synthesis to match GSH transport.
Some GSTs are actually protective against cigarette
smoke induced damage [29]. Carbon monoxide (CO)
levels are high in CS and CO is a known inhibitor of
heme-containing enzymes such as the cytochrome
P450s [30] and mitochondrial complexes [31]. CO has
well recognized protective effects in models associated
with oxidative stress [32] and is a known inducer of
GCL [33]. In terms of actual lung disease, a possible
scenario may be that symptoms, including excessive
inflammation and oxidative stress, may be tied to these
a d a p t i v er e s p o n s e sa n dm a yo n l yb e g i nt oa r i s ew h e n
these adaptive responses fail.
There are many studies that have examined the link
between antioxidants and inflammatory and oxidative
pathways. ELF GSH levels have been shown to be inver-
sely correlated with proinflammatory cytokine release
both in vitro and in vivo [16,34]. Furthermore, the
depletion of GSH has been widely shown to exacerbate
oxidative stress and oxidative modifications of molecules
[35-37]. GSH is a critically important molecule in both
direct reactions with oxidants as well as several enzy-
matic detoxification pathways. Despite this, there are
instances where the ability to synthesize GSH, and in
turn establish an adaptive response is compromised. For
instance, the normal aging process results in impaired
GSH synthesis capability resulting in as much as a 50%
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Interestingly, aging is an independent risk factor for
COPD [38]. The age-related decline in the ability to
synthesize GSH results in not only lower basal levels of
GSH, but also a decreased adaptive response to CS.
Moreover, aged mice have been shown to be more sus-
ceptible to the release of proinflammatory cytokines and
DNA oxidation from the same CS exposure than young
mice with proper robust adaptive responses [16]. A
number of genes involved in GSH synthesis, utilization,
and transport have been shown to have polymorphisms
associated with many lung diseases including COPD.
For instance, a number of variants in the GCL gene
have been associated with cystic fibrosis [39], and
COPD [40]. The GSTs are enzymes responsible for con-
jugating xenobiotics with GSH and also are commonly
associated with lung diseases including COPD [41]. In
addition, the only known transporter that places GSH in
the ELF is CFTR, the gene defective in cystic fibrosis
[42]. These findings, along with the fact that the lung
can normally maintain GSH for long periods even with
the oxidant burden of CS, lend credence to the theory
that disease symptoms could arise when adaptive
responses fail or are dysfunctional.
Conclusions
The present study has shown that many of the changes
in GSH with regard to CS occur very acutely and can be
maintained for longer periods of time. Furthermore, the
ELF GSH levels that are maintained may in fact be tied
to the CS induced depletion of GSH and that the lung
may utilize GSH originating from other sources such as
the liver and plasma to generate the high levels of ELF
G S H .T h e s ed a t ap r o v i d em o r ei n s i g h ti n t ot h ea c u t e
effects of CS and how the lung resists the oxidant effects
of CS. Examining the adaptive processes that are estab-
lished to respond to the initial CS burden may help to
understand what pathways become defective or are
compromised and may contribute to the pathogenesis of
COPD.
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